A new class of drug called siRNA, a cousin of mRNA, can enter cells and stop a specific gene from producing a harmful protein. This enables highly targeted treatments, such as new drugs that reduce a type of cholesterol by over 95% with a single, long-lasting injection.

After decades of work, small interfering RNA (siRNA) has overcome delivery challenges to become a mature, "de-risked" platform, primarily for liver-directed targets. This now enables powerful medicines like a once-yearly injection for high cholesterol, representing a major public health breakthrough.

The approvals of two different oligonucleotide constructs for the same indication (Arrowhead's siRNA vs. IONIS's ASO) mark a significant milestone. This direct competition between RNA modalities signifies a maturing market where companies now focus on determining which molecule is superior for specific targets.

Instead of remaining a pure-play antisense oligonucleotide (ASO) company, Ionis's CEO diversified into siRNA and gene editing. He recognized that the company's core expertise in oligonucleotide therapeutics was broadly applicable, a move that energized the research organization.

The commercial advantage of one-time CRISPR/Cas9 therapies is shrinking. Advancements in RNA modalities like siRNA now offer durable, long-lasting effects with a potentially safer profile. This creates a challenging risk-reward calculation for permanent gene edits in diseases where both technologies are applicable, especially as investor sentiment sours on CRISPR's long-term safety.

The industry is on the cusp of a seismic therapeutic shift. Major Phase 3 readouts for siRNA/ASO in common diseases are expected in the next year. Simultaneously, in vivo CAR-T for autoimmunity represents a move from treating symptoms to potentially curing diseases, a true revolutionary step.

For RNAi and antisense therapies targeting chronic conditions like cardiovascular disease, the critical competitive advantage is durability, not just efficacy. The ability to offer infrequent dosing, such as twice-yearly injections, represents a significant step-change from daily medications and is the key factor expected to drive market adoption.

Thalia's strategy isn't to compete with established players on single-target assets. Instead, it aims to create a new category with bispecific siRNAs that target multiple disease pathways simultaneously, combined with novel delivery systems to reach tissues beyond the liver.

Nuago leverages the 'seed-mediated off-target effect'—a bug for single-gene therapies—as a feature. Their short RNAs use a six-nucleotide seed to promiscuously target hundreds of survival and oncogenes, achieving a broad therapeutic effect where 'off-target' is the entire point, making unintended effects impossible.